- abnormal response/metabolism to endogenous compounds / MGI
- decreased circulating interleukin-6 level / MGI
- decreased sensitivity to induced morbidity/mortality / MGI
- decreased physiological sensitivity to xenobiotic / MGI
- decreased sensitivity to xenobiotic induced morbidity/mortality / MGI
- abnormal sleep pattern / MGI
- impaired central nervous system regeneration / MGI
- increased sensitivity to induced cell death / MGI
- increased susceptibility to bacterial infection induced morbidity/mortality / MGI
- impaired humoral immune response / MGI
- decreased susceptibility to bacterial infection / MGI
- decreased circulating alanine transaminase level / MGI
- abnormal Peyer's patch morphology / MGI
- abnormal immune system physiology / MGI
- abnormal lymph node B cell domain morphology / MGI
- abnormal Peyer's patch follicle morphology / MGI
- increased susceptibility to bacterial infection / MGI
- decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
- increased susceptibility to parasitic infection / MGI
- increased susceptibility to type I hypersensitivity reaction / MGI
- decreased Peyer's patch number / MGI
- absent follicular dendritic cells / MGI
- decreased IgG1 level / MGI
- decreased interleukin-6 secretion / MGI
B6.129P2-Tnfrsf1atm1Blt/Cnrm
Status | Available to order |
EMMA ID | EM:02523 |
International strain name | B6.129P2-Tnfrsf1atm1Blt/Cnrm |
Alternative name | B6.129S/SvEv-Tnfrsf1a |
Strain type | Targeted Mutant Strains : Knock-out |
Allele/Transgene symbol | Tnfrsf1atm1Blt, |
Gene/Transgene symbol | Tnfrsf1a |
Information from provider
Provider | Horst Bluethmann |
Provider affiliation | Pharmaceuticals Divisons, F. Hoffmann-La Roche Ltd. |
Genetic information | A genomic fragment containing exons II and III and 5' sequences from exon IV of the Tnfrsf1a gene was replaced by a neomycin resistance gene flanked by phosphoglycerate kinase-1 (pgk-1) promoter and poly (A)+ signal sequences. The insertion of the neo cassette resulted in the introduction of new BglII and StuI sites which were used to confirm the targeting event. The Tnfrsf1a homologies provided at both sides of the neo cassette were 868 bp and ~ 5 kb, respectively. The targeting vector was linearized with XbaI before electroporation into E14 embryonic stem cells derived from 129/Sv mice. |
Phenotypic information | Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. |
Breeding history | Backcrossed for 10 generations to C57BL/6, then intercrossed to generate a homozygous mutant line. |
References |
|
Homozygous fertile | yes |
Homozygous viable | yes |
Homozygous matings required | yes |
Immunocompromised | yes |
Information from EMMA
Archiving centre | CNR, Consiglio Nazionale delle Ricerche, Monterotondo, Italy |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- Tumor necrosis factor receptor 1 associated periodic syndrome / Orphanet_32960
MGI phenotypes (allele matching)
Literature references
- Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes.;Rothe J, Lesslauer W, Lötscher H, Lang Y, Koebel P, Köntgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H, ;1993;Nature;364;798-802; 8395024
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).